<h1 itemprop="aspect"> <strong>Kyprolis Side Effects</strong></h1><h1><img class="alignright size-full wp-image-3535" alt="kyprolis injection" src="http://www.bad-drug.net/wp-content/uploads/2012/09/kyprolis.jpg?1df917" width="200" height="239" pagespeed_url_hash="2621797871" onload="pagespeed.CriticalImages.checkImageForCriticality(this);"/>Serious Side Effects of Kyprolis</h1><ul><li>Severe cardiac adverse reactions have been observed. Kyprolis may cause <strong>heart failure</strong> or ischemia, which is an insufficient blood supply to an organ.</li></ul><h2>Common Side Effects of Kyprolis</h2><ul><li>You may experience fatigue after a Kyprolis treatment.</li><li>Kyprolis  may cause low blood cell count and thrombocytopenia (low platelet levels).</li><li>Trouble breathing, diarrhea, and fever have also been reported as side effects of taking Kyprolis.</li></ul></div><div class="v" id="tab2" ><h2 itemprop="aspect"> <strong> Warnings & Recalls for Kyprolis </strong></h2><h2>Kyprolis Warnings</h2><ul><li>Kyprolis may be toxic to a fetus. Do not take Kyprolis if you are pregnant or plan to become pregnant.</li><li>To prevent infusion reactions take dexamethasone.</li><li>Ensure that you are adequately hydrated to prevent Tumor Lysis Syndrome.</li><li>Stop Kyprolis doses if you experience symptoms of decreased liver function. Signs include yellowing of the skin or eyes (jaundice), darkened urine, and light colored stool.</li></ul></div><div class="v" id="tab3" ><h2 itemprop="aspect"> <strong> Kyprolis Treatment and Use </strong></h2><p><strong>Kyprolis</strong> | carfilzomib is an antineoplastic injection for patients with <strong>multiple myeloma</strong>. It is only approved for patients who have already received <strong>Velcade</strong> and <strong>immunomodulatory therapy</strong>. Patients should also exhibit a progression in their disease after 60 days of the last completed therapy before taking Kyprolis.</p><h2>How does Kyprolis work?</h2><p>Kyprolis is a proteasome inhibitor. Proteasomes are groups of cells that break down proteins. Kyprolis decreases proteasome activity in the blood and tissues, delaying the growth of tumors.</p><h2>Kyprolis Dosage Information</h2><p>Kyprolis is an injection which should be administered on two consecutive days a week for three weeks. Twelve days should separate treatment cycles. Treatment with Kyprolis is continued until toxicity levels become dangerous or the myeloma progresses.</p></div><div class="v" id="tab4" ><h2 itemprop="aspect"> Other Names for Kyprolis</h2> <strong>Brand name:</strong><br/><ul><br/><li>Kyprolis</li><br/></ul><br/> <strong>Generic name:</strong><br/><ul><br/><li>Carfilzomib</li><br/></ul></div><div class="v" id="tab5" ><h2 itemprop="aspect"> <strong> Lawsuits & Legal Information for Kyprolis </strong></h2>